Trials in Chicago, Illinois
Here are the top 10 medical studies for lung cancer in Chicago, Illinois
Popular Filters
Phase 3 Trials
Chemotherapy
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Chicago, Illinois
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Radiation Therapy
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Brain Metastasis from Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus for the treatment of small cell lung cancer that has spread to the brain.
Checkpoint Inhibitor
Ociperlimab + Tislelizumab vs Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 3
Goshen, Indiana
This trial is testing a combination of two drugs, ociperlimab and tislelizumab, to see how well they work together. Tislelizumab is an anti-PD-1 antibody developed by BeiGene, showing promise in various cancers and approved in China for several uses. It targets adults with a specific type of advanced lung cancer that has high levels of a protein called PD-L1. The drugs aim to boost the body's immune system to better recognize and attack cancer cells.
Small Molecule Drug
Adagrasib vs Docetaxel for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Chemotherapy
Chemoradiation + Pembrolizumab/Olaparib for Small Cell Lung Cancer
Recruiting1 awardPhase 3
Chicago, Illinois
This trial will compare overall survival and progression free survival of two groups of patients with advanced solid tumors - those who receive concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib, and those who receive concurrent chemoradiation therapy alone.
Trials With No Placebo
Monoclonal Antibodies
Patritumab Deruxtecan for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.
CAR T-cell Therapy
Autologous LN-145 for Lung Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
This trial tests LN-145, a treatment using a patient's own lab-prepared immune cells, in patients with advanced lung cancer that has spread. The process includes reducing existing immune cells, infusing enhanced ones, and boosting their activity.
Chemotherapy
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Chicago, Illinois
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Monoclonal Antibodies
Brentuximab Vedotin + Pembrolizumab for Advanced Cancers
Recruiting1 awardPhase 2
Chicago, Illinois
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer, including metastatic cancer that has progressed after PD-1 inhibitor treatment. The study will also find out what side effects occur.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.